The Challenge of Tuberculosis Infection Related to Adalimumab: A Subtle and Rare Presentation

Juliana Lopesa, e, Ana Machadoa, Sara Martinsa, Sara Piresa, Catarina Brancoa, Joana Fragoso, Diogo Guerra, Patricia Campos, Mariana Brandaoa, d, Graziela Carvalheiras, d, Teresa Mendonca, d

Abstract

With the increasing use of biological therapies, there was a concomitant increase in concern and sensitivity for associated opportunistic infections. There has been growing evidence that anti-tumor necrosis factor (TNF) therapy increases the risk of opportunistic infection. Screening for latent tuberculosis (TB) prior to initiation of therapy has reduced the incidence of active TB, although it is not completely preventable. The possibility of active TB should always be considered in immunosuppressed patients under anti-TNF therapy. We report a case of muscular TB with psoas abscess in a patient under adalimumab. This case highlights the importance of the high suspicion threshold for Mycobacterium tuberculosis infection, in patients with subtle symptoms.

Keywords: Tuberculosis; Psoas muscle abscess; Anti-TNF; Adalimumab; Intestinal Behcet

Introduction

The use of anti-tumor necrosis factor (TNF) has dramatically improved the approach to immune-mediated diseases. However, there is a concomitant increase in concern and sensitivity for associated opportunistic infections [1]. These agents suppress activity of TNF, a proinflammatory cytokine crucial for human response to infection. In fact, several opportunistic infections have been described in association with therapy with anti-TNF [2, 3]. The first randomized anti-TNF trial has described only one case of tuberculosis (TB) infection. Since then, there has been growing evidence that anti-TNF therapy increases the risk of TB infection, with a possible difference between the three anti-TNF drugs used: infliximab and adalimumab with higher associated risk than etanercept [4, 5].

Screening for latent TB prior to initiation of therapy has reduced the incidence of active TB, although it is not completely preventable. There are cases of disease reactivation even after adequate treatment at the start of biological therapy. The possibility of active TB should always be considered in cases with suggestive clinical features or suspect imaging findings, even after chemoprophylaxis [3, 6]. Portugal has an intermediate incidence of TB (22 cases per 100,000 inhabitants in 2016) compared to the rest of Europe; as a result, patients on anti-TNF therapy will have, therefore, a higher incidence of infection [7, 8].

We report a rare case of extrapulmonary TB in a patient using adalimumab.

Case Report

This was a 59-year-old woman, Caucasian, with a previous history of osteoarticular TB (Pott’s disease) at the age of 7 years old. Since then, she had no history of infection or contact with other TB patients.

She was diagnosed as Behcet’s disease with a 23-year-old history of outbreaks of oral ulcers. Since the age of 55 years, she started with severe gastrointestinal manifestations, irresponsible to corticosteroids and infliximab. She began adalimumab treatment 3 years ago with clinical improvement. Before anti-TNF therapy, she completed 9 months of isoniazid for latent tuberculosis.

The patient presented with high fever, asthenia and night sweats for 1 month, without other symptoms associated. Blood tests were innocent, with a slight protein C elevation. Blood and urine cultures were sterile. Pulmonary X-ray and abdominal ultrasound didn’t reveal any findings. After 2 weeks of the first symptoms, she complained with left pain, without trauma associated. Computed tomography (CT) scan revealed a left psoas muscle mass (diameter 4 - 14 cm with calcifications). She was submitted to percutaneous drainage of the abscess and the microbiologic study revealed nucleic acid amplification.

Manuscript submitted December 3, 2017, accepted December 8, 2017

aInternal Medicine Department, Centro Hospitalar do Porto, Porto, Portugal
bIntensive Care Department, Centro Hospitalar do Porto, Porto, Portugal
cClinic Immunology Unit, Centro Hospitalar do Porto, Porto, Portugal
dCorresponding Author: Juliana Lopes, Internal Medicine Department, Centro Hospitalar do Porto, Hospital de Santo Antonio, Largo Prof. Abel Salazar, 4099-001, Porto, Portugal. Email: mariajulopes@gmail.com

doi: https://doi.org/10.14740/jmc2979w

The article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
fication (NAA) test positive for *Mycobacterium tuberculosis*, which was also detected in cultures.

The patient began treatment with classic association of antibiotics that included isoniazid, rifampicin, pyrazinamide, and ethambutol for 9 months with complete resolution of the abscess (Fig. 2).

**Discussion**

The introduction of anti-TNF therapy drastically altered the approach to immune-mediated diseases. TNF plays a key role in host defense against *Mycobacterium tuberculosis*, mediating granuloma formation and homeostasis and consequent bacilli content in latent TB infection [9]. Consequently, a number of cases of TB have been documented in patients under anti-TNF therapy such as etanercept, infliximab, and adalimumab [10]. This risk appears to be 3 to 4 times higher with infliximab and adalimumab when compared to etanercept [11]. It is believed that most cases are consecutive of latent TB reactivation and therefore, in countries with high or intermediate incidence, the screening is recommended before initiation of therapy and treated accordingly. Several studies have shown that chemoprophylaxis of latent TB before or during anti-TNF therapy reduces the risk of reactivation and consequently more severe forms of infection [9].

In clinical trials prior to the screening for TB, only 7 cases of active infection were reported in Europe. After the introduction of the screening in adalimumab clinical trials, there was an increase in the number of cases to 23 cases until 2005 and 59 cases until 2014 [12, 13].

In the present case, the active infection was documented despite screening and treatment of latent TB, and is a rare extrapulmonary presentation.

The psoas abscess was first described in 1881 [14] and remains a rare infection in developed countries. It can be termed as primary if the focus is unknown or by hematogenous spread or secondary if there is an abdominal or retroperitoneal infec-

**Figure 1.** Abdominal CT scan showing left psoas muscle mass with the diameter 4 - 14 cm. CT: computed tomography.

**Figure 2.** Abdominal CT scan with resolution of the abscess after 9 months of antibacillar therapy.
tion. It is usually caused by *Staphylococcus aureus*, or other agents present in intestinal flora [15]. The immunosuppression is one of the major associated risk factors and for this reason, agents such as *Mycobacterium tuberculosis* should be consid-
ered.

Although several cases of extrapulmonary infection have been described [16-19], the authors only found one case of muscular TB in patients with adalimumab in literature [20].

This case highlights the importance of the high suspicion threshold for *Mycobacterium tuberculosis* infection. In immunocompromised patients, the clinical presentation is usually very subtle, extrapulmonary and rare forms are more frequent and may progress rapidly to more severe forms. Adequate early and therapeutic diagnosis will allow improving the long-

**Conflict of Interest**

There is no conflict of interest.

**Financial Support**

No external funds were used for this research study.

**References**


